Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Hoffmann-La Roche
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Adult patients, \>/= 18 years of age
Histologically or cytologically confirmed soft tissue sarcoma
Evaluable disease according to RECIST version 1.1 criteria
Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1
Eligible for doxorubicin therapy
Acute toxicities from prior anti-tumor therapy, surgery or radiotherapy must have resolved to NCI-CTCAE Grade \</= 1 prior to start of study
Adequate bone marrow, hepatic and renal function
Patients with stable CNS metastases are eligible
You may not be if
Previous treatment with limiting doses of doxorubicin
Patients receiving any other investigational or commercial agents or therapies administered with the intention to treat their malignancy or other ailment \</= 28 days from Day 1 dosing on study treatment
History of seizure disorders or unstable CNS metastases
Severe and/or uncontrolled medical conditions or other conditions that could affect the participation in the study
Pregnant or breastfeeding women
HIV positive patients who are currently receiving combination anti-retroviral therapy
Patients with known coagulopathy, platelet disorder or history of non-drug induced thrombocytopenia
Patients receiving oral or parenteral anti-coagulants/anti-platelet agents
